Tyra Biosciences sets September 2026 SURF302 data, reports $353.9 million cash

The biotech said initial Phase 2 bladder cancer data will include safety from more than 40 patients, while achondroplasia results from about 25 children are now expected by the end of Q1 2027.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.